Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court

Good News For Gene Therapy Continues As FDA Also Removes Hold On Voyager’s Huntington’s Trial

Executive Summary

While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.

You may also be interested in...



Accelerated Assessment Success In EU For CSL Behring And Roche

There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted. 

Five Hematology Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.

UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez

The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel